Tsuchimochi S, Nakajo M, Umanodan T, Fukushima N, Shigaki S, Kiku T
Department of Radiology, Kagoshima University Hospital.
Kaku Igaku. 2001 Nov;38(6):747-54.
In Japan, a new guideline for the release of patients administered 131I was issued by the Ministry of Welfare on June, 1998: The dose rate is under 30 microSv/h at 1 m or the activity in the body is under 500 MBq. This study was designed to set the appropriate isolation period enough to satisfy these limits. A total of 28 patients with the history of total thyroidectomy and metastasis were selected for this study. In these patients, 28 patients were treated with oral administration of 3.7 GBq of Na131I (72 times), and one of 28 patients was once treated with 5.55 GBq of Na131I. Two of them were also received a total of 4 courses of a split dose therapy of 3.7 GBq of Na131I (740 MBq once a week for 5 consecutive weeks = one course). Measurements of the external exposure dose (microSv/h) at 1 m and the urinary excretory radioactivity (MBq) were performed at various times. There was a good correlation of the external exposure dose between standing (x microSv/h) and sitting (y microSv/h) postures (y = 0.99x + 0.406, r = 0.99, p < 0.0001, n = 169). The difference in the external exposure dose before and after urination (x microSv/h) had a significant correlation with the urinary excretory radioactivity (y MBq); y = 16.6x + 24.8, r = 0.96, p < 0.001, n = 41. Also, there was a significant correlation between the predicted value of residual radioactivity in the body (y' MBq) and the external exposure dose (x' microSv/h); y' = 20.8x' + 31.5, r = 0.98, p < 0.001, n = 77. In the patients treated with 3.7 GBq of Na131I, the mean and S.D. values of the external exposure dose (microSv/h) changed as follow: After 6 hr, 168 +/- 40; 24 hr, 52 +/- 23; 48 hr, 20 +/- 15; 72 hr, 10 +/- 9; and 96 hr, 8 +/- 9. The percentages of the patients satisfied the new guideline were as follow; 21.7% at 24 hr, 81.2% at 48 hr and 100% after 72 hr. Therefore the 3-day isolation is sufficient for the patients administered 3.7 GBq of Na131I.
1998年6月,日本厚生省发布了一项关于131I治疗患者出院的新指南:距离患者1米处的剂量率低于30微希沃特/小时,或体内放射性活度低于500兆贝可。本研究旨在确定足以满足这些限制的适当隔离期。本研究共选取了28例有甲状腺全切及转移病史的患者。在这些患者中,28例患者口服3.7吉贝可的碘化钠131I进行治疗(共72次),28例患者中有1例曾接受5.55吉贝可的碘化钠131I治疗。其中2例还接受了总共4个疗程的3.7吉贝可碘化钠131I分剂量治疗(每周1次,每次740兆贝可,连续5周为1个疗程)。在不同时间测量了距离患者1米处的外照射剂量(微希沃特/小时)和尿排泄放射性活度(兆贝可)。站立姿势(x微希沃特/小时)和坐姿(y微希沃特/小时)下的外照射剂量之间存在良好的相关性(y = 0.99x + 0.406,r = 0.99,p < 0.0001,n = 169)。排尿前后的外照射剂量差异(x微希沃特/小时)与尿排泄放射性活度(y兆贝可)有显著相关性;y = 16.6x + 24.8,r = 0.96,p < 0.001,n = 41。此外,体内残留放射性活度的预测值(y'兆贝可)与外照射剂量(x'微希沃特/小时)之间存在显著相关性;y' = 20.8x' + 31.5,r = 0.98,p < 0.001,n = 77。接受3.7吉贝可碘化钠131I治疗的患者,外照射剂量(微希沃特/小时)的平均值和标准差变化如下:6小时后,168±40;24小时后,52±23;48小时后,20±15;72小时后,10±9;96小时后,8±9。符合新指南的患者百分比如下:24小时时为21.7%,48小时时为81.2%,72小时后为100%。因此,对于接受3.7吉贝可碘化钠131I治疗的患者,3天隔离就足够了。